Dr. Anthony J. Olszanski
Claim this profileFox Chase Cancer Center
Expert in Solid Tumors
Studies Melanoma
17 reported clinical trials
24 drugs studied
Area of expertise
1Solid Tumors
Global LeaderStage IV
Stage III
advanced
2Melanoma
Stage IV
Stage III
BRAF
Affiliated Hospitals
Clinical Trials Anthony J. Olszanski is currently running
EU101
for Solid Cancers
Phase 1 (Dose Escalation) of this study will assess the safety, tolerability, dose-limiting toxicity (DLT), and will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of EU101 in participants with advanced solid tumors. Phase 2 (Dose Expansion) of the study will assess the antitumor effect of EU101 in two indications including colorectal cancer (CRC) and non-small cell lung cancer (NSCLC).
Recruiting1 award Phase 1 & 210 criteria
CBL0137 + Immunotherapy
for Melanoma
Phase I, open label, dose-escalation, and safety study designed to assess the safety and biologic activity of the investigational agent CBL0137 in combination with standard of care drugs, ipilimumab and nivolumab in sequential cohorts of adult patients with locally advanced and metastatic melanoma who are candidates for immune checkpoint blockade and have tumors accessible for serial biopsies.
Recruiting1 award Phase < 15 criteria
More about Anthony J. Olszanski
Clinical Trial Related4 years of experience running clinical trials · Led 17 trials as a Principal Investigator · 9 Active Clinical TrialsTreatments Anthony J. Olszanski has experience with
- Nivolumab
- Gamitrinib
- CBL0137
- Ipilimumab
- KD033 (SAR445710)
- Low Dose Radiation
Breakdown of trials Anthony J. Olszanski has run
Melanoma
Pancreatic Cancer
Skin Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Anthony J. Olszanski specialize in?
Anthony J. Olszanski focuses on Solid Tumors and Melanoma. In particular, much of their work with Solid Tumors has involved Stage IV patients, or patients who are Stage III.
Is Anthony J. Olszanski currently recruiting for clinical trials?
Yes, Anthony J. Olszanski is currently recruiting for 9 clinical trials in Philadelphia Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Anthony J. Olszanski has studied deeply?
Yes, Anthony J. Olszanski has studied treatments such as Nivolumab, Gamitrinib, CBL0137.
What is the best way to schedule an appointment with Anthony J. Olszanski?
Apply for one of the trials that Anthony J. Olszanski is conducting.
What is the office address of Anthony J. Olszanski?
The office of Anthony J. Olszanski is located at: Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 United States. This is the address for their practice at the Fox Chase Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.